AMENDMENTS TO THE CLAIMS

Please amend the Claims as follows.

Claims 1-22 (Cancelled)

23. (Thrice Amended) A method of transfecting antigen presenting cells, the steps comprising

selecting a gene delivery complex that targets antigen presenting cells, comprising DNA and ~~a compound~~ one or more compounds selected from the group consisting of sugars, polyethylenimine, and polyethylenimine derivatives,

and applying the complex to the skin or mucosa surfaces of an animal,

wherein said DNA comprises a nucleic acid sequence encoding at least one immunogenic protein operatively linked to a promoter.

24. (Previously presented) The method of Claim 23, wherein the compound is selected from the group consisting of glucose and polyethylenimine derivatives.

25. (Previously presented) The method of Claim 24, wherein the polyethyleneimine derivative targets the mannose receptor found on the surface of antigen presenting cells.

26. (Previously presented) The method of Claim 25, wherein the derivative is mannosylated polyetheylenimine.

27. (Cancelled).

28. (Previously presented) The method of Claim 23, wherein the complex is electrostatically neutral.

29. (Cancelled)

30. (Previously presented) The method of Claim 28, wherein the complex comprises a 5:1 ratio of polyethylenimine derivative nitrogen per DNA phosphate.

31. (Previously presented) The method of Claim 23, wherein the gene delivery complex is formulated in a glucose solution.

32. (Previously presented) The method of Claim 31, wherein the glucose solution is 5-10% glucose.

33. (Previously presented) The method of Claim 32, wherein the glucose solution is 8% glucose.

34. (Cancelled)

35. (Previously presented) The method of Claim 23, further comprising one or more steps selected from the group consisting of receptor stimulation, toxin activation, tissue injury and cell injury.

36. (Cancelled)

37. (Previously presented) The method of Claim 23, wherein the protein is from a human immunodeficiency virus.

38. (Previously presented) The method of Claim 37, wherein the human immunodeficiency virus is replication-defective.

39. (Previously presented) The method of Claim 38, wherein the human immunodeficiency virus is integration-defective.

40. (Previously presented) The method of Claim 23, wherein the DNA is a plasmid.

41. (Previously presented) The method of Claim 23, wherein the cells are Langerhans cells.

42. (Previously presented) The method of Claim 29, wherein the complex comprises a 3:1 ratio of polyethylenimine nitrogen per DNA phosphate.

43. (Previously presented) The method of Claim 25, wherein the derivative is a sugar-modified polyethylenimine.